Management Team

bill

William T. Sharp, Co-founder, CEO & Director

With more than thirty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size, and Fortune 100 public companies in the medical device, diagnostics, and life science tools and services markets. Mr. Sharp has served in senior leadership roles with five venture-backed companies – as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen). Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.

5

Stephen Ilsley, Director of Product Development

Mr. Ilsley is a seasoned product development leader with over three decades in research, development, commercialization and marketing of instruments, reagents, assay kits and consumables. Mr. Ilsley’s experience spans startups to Fortune 500 companies. He began his career at Collaborative Research where he helped established the company as a leading supplier of specialty tools for cell culture research. Following acquisition by BD Biosciences, he continued in Product Development as Senior R&D Scientist and Business Team Leader and was responsible for commercializing hundreds of highly successful products. Following his tenure at BD, Mr. Ilsley joined IDEXX Laboratories, a veterinary diagnostics company, as Scientific Group Leader in the Rapid Assay Immuno-diagnostic R&D group. Subsequent to IDEXX, Mr. Ilsley moved to Life Technologies where, as Senior Product Manager, he was responsible for the global management of chemiluminescent reagents, assay kits, immunodetection products and imaging instrumentation. Most recently, he was Applications Marketing Manager at Xcellerex (GE Healthcare). Mr. Ilsley earned his B.A. degree in Biology at Northeastern University.

4

Jay Rau, Director of Business Development

Mr. Rau’s career extends over three decades in sales, sales management, business development, basic research and product development. His experience spans venture-backed businesses, mid-size, and Fortune 500 public companies in the medical device, diagnostics, and life science tools and services markets. Mr. Rau’s venture-backed experience includes his most recent role as Director of Business Development for Spartan Bioscience in which he successfully established global distribution channels plus engaged in the initiation and direction of collaborative partnerships. Previous business development, sales, and sales management experience includes fourteen years with Gentra Systems (acquired by Qiagen) where he held all sales records, Sequenom, and Pall Corporation. During his early career, Mr. Rau gained basic research and product development experience at Kallestad (now owned by Danaher – Beckman Coulter), the University of Wisconsin and the University of Minnesota. Mr. Rau earned his B.S. degree from the University of Wisconsin – Madison.

7

Bob Gallahue, Advisor, CFO

Mr. Gallahue has over 20 years of financial management experience in public and private biotechnology and medical technology companies in the various facets of start‐up through public company environments, including three IPOs, three mergers, joint ventures, private financings and follow‐on offerings. Mr. Gallahue has served as CFO of CorNova, Inc., Cibiem Inc., Molecular Insight, and Keryx Biopharmaceuticals and has worked in high level financial positions at Millennium Pharmaceuticals and LeukoSite Inc. He started his career at PricewaterhouseCoopers, LLP where he was a C.P.A. responsible for auditing. Mr. Gallahue holds a M.S.A. from Bentley College and B.A. from Middlebury College.

3

Leonard Klevan, Ph.D., Scientific Advisor & Consultant

Dr. Klevan brings more than three decades of experience in executive management, R&D, technology acquisition and business development to DxNow. He was President of the Human Identification Business at Life Technologies Corporation, which develops and markets products for forensic DNA testing and other forms of human identification. An internationally recognized leader in the DNA Identification field, Dr. Klevan received the 2008 Leadership Award from the National Center for Victims of Crime “for advancing new DNA technologies that enhance criminal investigations and give hope to crime victims and their families.” Prior to Life Technologies, Dr. Klevan was President of the Applied Markets Division at Applied Biosystems. The Applied Markets Division developed and marketed products in the fields of human identity testing, biosecurity, and quality and safety testing in food, pharmaceutical manufacturing and the environment. Before Applied Biosystems, he was Chief Executive Officer of ReliaGene Technologies, a forensic and paternity testing laboratory and previously was President and CEO of MiraiBio (Hitachi Genetic Systems), a subsidiary of Hitachi Software Engineering. Earlier in his career, Dr. Klevan managed R&D, technology acquisition and business development for Life Technologies before that company was acquired by Invitrogen. Dr. Klevan earned a Ph.D. in Physical Chemistry from Yale University and received his postdoctoral training at Harvard.

6

Kevin Sly, Senior Advisor, Strategic Marketing & Corporate Development

Bringing over 25 years of experience in the pharmaceutical, biomedical and biotechnology industries to DxNow, Mr. Sly currently leads the strategic marketing and corporate development efforts for the company’s expanding commercialization efforts. Prior to joining the DxNow team, Mr. Sly directed the commercial strategy, marketing and business development activities for Baltimore-based Paragon Bioservices. Throughout his career, Mr. Sly’s focus has primarily been strategic marketing and business development, from leading the efforts in pharmaceutical technology licensing and product development (including Phase I–III development and commercial manufacturing), to the development of business strategy and strategic commercial development for a range of biopharmaceutical products. Mr. Sly joined the Maryland business community in 2002 as Chief Business Officer for a private start-up, Advancis Pharmaceutical Corporation, playing a critical role in establishing a strong marketing presence, delivering key validating licensing and acquisition deals, serving on the core IPO deal team and leading the post-IPO efforts to establish the company’s first commercial operations. He received his BA in Biology (pre-med) from Pomona College.

BOARD OF DIRECTORS

bill

William T. Sharp, Co-founder, CEO & Director

With more than thirty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size, and Fortune 100 public companies in the medical device, diagnostics, and life science tools and services markets. Mr. Sharp has served in senior leadership roles with five venture-backed companies – as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen). Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.

2

Utkan Demirci, Ph.D., Co-founder, Director, Scientific Advisor

Dr. Demirci is Professor with Tenure at Stanford University School of Medicine, Canary Center for Early Cancer Detection. He is a world-renowned expert in micro- and nano-scale biotechnologies. Prior to Stanford, Dr. Demirci was Associate Professor of Medicine, Harvard-MIT Health Sciences and Technology, Harvard University Medical School, Brigham and Women’s Hospital. He currently leads a team of more than 30 researchers focusing on nano- and micro-scale technologies. He has published over 60 peer reviewed journal publications in journals including PNAS, Advanced Materials, Biomaterials, Lab-on-a-Chip, Nanomedicine, over 100 conference abstracts and proceedings, and more than 10 book chapters. His work has been highlighted in Wired Magazine, MIT Technology Review Magazine, AIP News, BioTechniques, and Biophotonics. Dr. Demirci has been cited over 600 times in the past 2 years and has given over 50 national and international presentations including invited and keynote at various academic, governmental, and industrial institutions. In 2006, he was selected to TR-35 as one of the world’s top 35 young innovators under the age of 35 by the MIT Technology Review. Dr. Demirci received his B.S. degree in Electrical Engineering as a James B. Angell Scholar (Summa Cum Laude) from University of Michigan, Ann Arbor, his M.S. degree in Electrical Engineering, M.S. degree in Management Science and Engineering and Ph.D. in Electrical Engineering, all from Stanford University.

CLINICAL ADVISORY BOARD

Joseph V. Bonventre, M.D., Ph.D., Founding Member CAB

Dr. Bonventre is the Samuel A. Levine Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at the Massachusetts Institute of Technology. He is Chief of the Renal Division and Founding Chief of the Engineering in Medicine Division of the Brigham and Women’s Hospital. Dr. Bonventre’s research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. He has authored more than 340 original publications and 150 invited chapters, editorials and reviews and his work has been cited more than 47,000 times. He has received two MERIT awards from the NIH National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) and he now serves as a member of the Council of the NIDDK. Dr. Bonventre has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the American Institute for Medical and Biological Engineering. He was Director of the Harvard-MIT Division of Health Sciences and Technology for 10 years. He has received the National Kidney Foundation of MA, RI and Vermont Outstanding Physician Award. Dr. Bonventre currently is on the Executive Committee of the Harvard Stem Cell Institute where he was the founding head of the Kidney Group and now heads the Fibrosis Group. Dr. Bonventre is past-president of the American Society of Nephrology and member of the Council of the International Society of Nephrology. He is a founding member of the Board of Directors of the National Space Biology Research Institute. He has served on many NIH Study Sections and is Editor of Seminars in Nephrology. He has been awarded the Osler Medal of the Royal Society of Physicians and the Bywaters Award of the International Society of Nephrology and was voted one of three top mentors in the US by postdoctoral fellows in the journal “Science”, in 2004. In addition to his BS with distinction in Engineering Physics from Cornell, Dr. Bonventre holds M.D. and Ph.D. degrees in biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary’s College and from the Norwegian Institute of Science and Technology in Norway.

Barry Behr, Ph.D., H.C.L.D.

Dr. Behr is the Director of the IVF/ART Laboratory and Co-Director of the REI-IVF program, both at Stanford University, and is the Director of the Renew Biobank Institute for Stem Cell Biology and Regenerative Medicine. Dr. Behr is a nationally and internationally renowned clinical and scientific leader in the research and advances of human reproduction. As a world-renown scientist and lecturer, he is highly sought after to chair scientific programs and conferences, is the first non-MD President of the Pacific Coast Reproductive Society and has been appointed as program chairman of several professional meetings. Dr. Behr has been widely recognized for his research and has published over 200 peer-reviewed publications and book chapters.

Glenn M. Chertow, M.D., M.P.H.

Dr. Chertow is Professor of Medicine and Chief, Division of Nephrology, at Stanford University School of Medicine. Prior to joining the faculty at Stanford, Dr. Chertow served with distinction on the faculties at Brigham and Women’s Hospital and Harvard Medical School (1995-98) and the University of California San Francisco (UCSF) (1998-2007). Dr. Chertow has established a successful career as a clinical investigator and continues to maintain a productive research program focused on improving care for persons with acute and chronic kidney disease (CKD). Recent projects include several NIDDK-sponsored initiatives: Acute Renal Failure Trials Network (ATN) Study, the United States Renal Data System (USRDS) Special Studies Center in Nutrition, the Chronic Renal Insufficiency Cohort (CRIC) study and the Frequent Hemodialysis Network (FHN) study.

Dr. Chertow was elected to the American Society of Clinical Investigation in 2004 and appointed to the Scientific Advisory Board of the National Kidney Foundation in 2007.

Daniel Kuritzkes, M.D.

Dr. Kuritzkes is Chief, Division of Infectious Diseases at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.  He is also Head of the Section of Retroviral Therapeutics for the Harvard Division of AIDS and Principal Investigator of the Harvard Adult AIDS Clinical Trials Unit. Dr. Kuritzkes has published numerous articles on HIV antiretroviral therapy and has chaired several multicenter studies of HIV therapy. He also has published extensively on the problem of drug resistance in HIV infection and serves on the IAS-USA panel that developed guidelines for drug resistance testing. He has served on numerous NIH committees and chaired the HIV Disease Research Agenda Committee of the Adult AIDS Clinical Trials Group.

Dr. Kuritzkes is a member of the editorial boards of several journals and serves as an Associate Editor for the Journal of Infectious Diseases. Dr. Kuritzkes received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious disease at Massachusetts General Hospital.

Gianpiero D. Palermo, M.D., Ph.D.

Dr. Palermo is the pioneer of intracytoplasmic sperm injection (ICSI), a ground-breaking technique that has transformed the treatment of male factor infertility and fertilization failure. Ever since its inception in 1992, ICSI has assisted thousands of men to achieve biologic paternity. Beginning 1993, Dr. Palermo has been the Director of Assisted Fertilization and Andrology at the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, one of the world’s largest ICSI programs. In his capacity as the Blavatnik Distinguished Professor of Reproductive Medicine, he leads a talented team of researchers comprising of andrologists and clinical fellows who investigate the molecular aspects of fertilization, genetic and epigenetic aspects of male infertility, follow-up of ICSI babies and the development and differentiation of embryonic stem cells. He has published over 76 book chapters, 327 abstracts, and 132 research papers, which have been featured in journals such as the New England Journal of Medicine, Lancet, JAMA, Human Reproduction, Fertility and Sterility, and PLOS One. He is the recipient of multiple awards, including the Jacob Heskel Gabbay Award in Biotechnology and Medicine awarded by the Rosenstiel Basic Medical Sciences Research Center and Brandeis University, the Barbara Eck Menning Founders Award, and the Francavilla Fontana Illustrious Citizen Award.

Mitchell Rosen, M.D.

Dr. Rosen serves on the faculty at UCSF and is the Director of the UCSF Reproductive Laboratories and Fertility Preservation Program, one of the largest programs in the USA. He received his medical training at St. Louis University and completed his residency in Obstetrics and Gynecology at the University of Texas Medical Branch. Dr. Rosen subsequently received his training in Reproductive Endocrinology and Infertility at UCSF. He is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility. In addition, to further understand the IVF process, he also trained as an embryologist and serves as the laboratory director at UCSF. Knowledge of both the clinical and laboratory aspects of assisted reproduction has allowed him to focus his clinical work and research endeavors on optimizing IVF outcomes, and preserving fertility. As a result of his work, he has published numerous manuscripts and chapters that have significantly contributed to the field.

Ravi Thadhani, M.D., M.P.H.

Dr. Thadhani is Professor of Medicine at Harvard Medical School and the Director of Clinical Research in Nephrology and Chief of the Renal Unit at the Massachusetts General Hospital. Dr. Thadhani trained at the Massachusetts General Hospital, Harvard Medical School, where he has been since 1991. He was a Fellow in Nephrology between the years 1994-1998 and currently serves as the Director of Clinical Research in Nephrology. He has two major interests, preeclampsia and dialysis mortality. Dr. Thadhani has published more than 100 manuscripts in these and related areas. His focus is to bring novel therapies and diagnostics to patients with renal failure in hopes to improve outcomes. Dr. Thadhani is currently working on therapeutic strategies to alleviate the signs and symptoms of preeclampsia. He is also focused on the cardiovascular and infectious consequences of defective vitamin D signaling in subjects with renal failure. His team has performed several hypothesis-generating observational studies suggesting that therapy with activated vitamin D sterols is associated with improved survival among patients with renal failure. In addition, he has carried out a series of in-vivo studies in rodents which suggests that activated vitamin D sterols prevent the progression of cardiac hypertrophy and heart failure via inhibition of renin-angiotensin pathway and other pathways. Based on these observational human studies and in-vivo rodent experiments, he has initiated a multicenter randomized trial to test the hypothesis in humans.

Dr. Thadhani received his BS degree summa cum laude from The University of Notre Dame, his MD from the University of Pennsylvania, and his MPH from The Harvard School of Public Health. He spent a year as Chief Medical Resident at MGH, where he completed his training with a specialization in nephrology.

Nina Tolkoff-Rubin, M.D.

Dr. Tolkoff-Rubin is Director of the Hemodialysis & Chronic Ambulatory Peritoneal Dialysis Units, Massachusetts General Hospital.  She co-founded the Inter-American Foundation for Clinical Research in association with her husband, Robert H. Rubin, to foster clinical research throughout the Americas. A graduate of Harvard Medical School, Dr. Tolkoff-Rubin did her residency and nephrology training at the Massachusetts General Hospital and is currently Professor of Medicine, Harvard Medical School. She is also Director, Continuous Veno-Venous Hemofiltration (CVVH) Program and a member of the staff of the Renal Unit where she is director of Dialysis Services and Medical Director of the Renal Transplant Program at Massachusetts General Hospital.

Dr. Tolkoff-Rubin’s research has focused on the treatment of urinary tract infections in young women as well as immunocompromised hosts; the treatment of CMV infection in renal transplant recipients; the impact of biocompatible dialysis membranes on the outcome of acute renal failure; the definition and treatment of acute humoral rejection in renal transplant recipients; and the translation of tolerance protocols from bench to bedside – using simultaneous bone marrow kidney transplants in a non-myeloablative induction protocol to achieve mixed chimerism.

Paul Turek, M.D.

Dr. Turek is a board-certified urologist and microsurgeon, specializing in male fertility. He has performed and published research in men’s reproductive health issues including genetic infertility, ejaculatory duct obstruction, immunologic infertility, quality of life issues with infertility, testis cancer and stem cell science, and has developed several techniques for evaluating and treating male infertility. While at UCSF, he was Director of the Male Reproductive Clinical Laboratory, Program Leader of PROGENI (The Program in the Genetics of Infertility), Director of the UCSF Men’s Reproductive Health Clinic and Research Program, and the director of a National Institutes of Health grant to train new faculty in men’s reproductive health. He has authored more than 175 publications on clinical and scientific issues in reproductive health. Through his published work, he is a proponent of the theory that male infertility is an early marker for other diseases that occur later in life. He became a full professor, with an endowed chair in teaching funded by the Academy at UCSF, a chair he later abandoned in favor of starting his own private clinic.

He is now Director of The Turek Clinic, a medical center that specializes exclusively in men’s reproductive health care. The clinic is dedicated to treating the unique conditions that affect reproductive age men. He was President in 2011 of the American Society of Andrology.